Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study.

Edoardo Conticini,Miriana d'Alessandro,Silvia Grazzini,Chiara Rizzo,Marco Fornaro,Paolo Cameli,David Bennett,Anna Abbruzzese,Federica Camarda,Giuseppe Lopalco,Laura Bergantini,Paolo Falsetti,Elena Bargagli,Florenzo Iannone,Giuliana Guggino,Hector Chinoy,Luca Cantarini,Bruno Frediani

Clinical and experimental rheumatology（2023）

Cited 0|Views11

No score

Abstract

Hypogammaglobulinaemia following RTX is uncommon in IIM and is not related to any clinical variables, including GC dosage and previous treatments. IgG and IgM monitoring after RTX treatment does not seem useful in stratifying patients who require closer safety monitoring and prevention of infection, due to the lack of association between hypogammaglobulinaemia and the onset of severe infections.

Translated text

Key words

rituximab,myositis,hypogammaglobulinaemia

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined